Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
0.8299 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|
Revenue
| 5.124 | 9.032 | 12 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 1.164 | 0.725 | 0.472 | 0.229 | 0.257 | 0.02 | 0 | 0 |
Gross Profit
| 3.96 | 8.307 | 11.528 | -0.229 | -0.257 | -0.02 | 0 | 0 |
Gross Profit Ratio
| 0.773 | 0.92 | 0.961 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 20.295 | 12.198 | 15.929 | 15.673 | 15.436 | 12.826 | 3.73 | 1.709 |
General & Administrative Expenses
| 0 | 17.405 | 26.979 | 24.508 | 14.644 | 9.052 | 0.727 | 0.204 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 46.887 | 17.405 | 26.979 | 24.508 | 14.644 | 9.052 | 0.727 | 0.204 |
Other Expenses
| -0.014 | -0.058 | 0 | -0.001 | 1.873 | -0.001 | 0 | 0 |
Operating Expenses
| 67.182 | 29.603 | 42.908 | 40.181 | 30.08 | 21.878 | 4.457 | 1.913 |
Operating Income
| -63.222 | -21.296 | -30.908 | -40.181 | -30.08 | -21.878 | -4.457 | -1.913 |
Operating Income Ratio
| -12.338 | -2.358 | -2.576 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| -3.773 | -3.191 | -4.172 | -2.513 | 1.873 | -0.001 | -0.002 | 0 |
Income Before Tax
| -66.995 | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 | -4.459 | -1.913 |
Income Before Tax Ratio
| -13.075 | -2.711 | -2.923 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0.668 | 3.191 | 3.823 | 2.803 | -0.257 | 1.23 | -4.457 | -1.913 |
Net Income
| -66.995 | -27.678 | -38.903 | -45.497 | -27.95 | -20.648 | -4.459 | -1.913 |
Net Income Ratio
| -13.075 | -3.064 | -3.242 | 0 | 0 | 0 | 0 | 0 |
EPS
| -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.096 |
EPS Diluted
| -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.096 |
EBITDA
| -62.386 | -20.878 | -30.785 | -39.661 | -30.08 | -20.648 | -4.457 | -1.913 |
EBITDA Ratio
| -12.175 | -2.312 | -2.565 | 0 | 0 | 0 | 0 | 0 |